Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Clinical trial NCT07422363 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07422363
Sponsor: National Cancer Institute (NCI)
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Glioblastoma, IDH-Wildtype Recurrent Gliosarcoma Recurrent WHO Grade 4 Glioma

Start date: 2026-12-04
Primary completion: 2027-02-28
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.